Published in J Clin Oncol on April 15, 2001
Proton Radiation for Resectable Carcinoma of the Pancreas (PC02) | NCT00763516
Capecitabine in Metastatic Breast and GI Cancers (X7-7) | NCT02595320
Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer | NCT01584544
Prevention of Capecitabine Induced Hand and Foot Syndrome | NCT01291628
Proton Therapy for Unresectable Cancer (CA) of Pancreas (PC01) | NCT00685763
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol (2015) 2.70
Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer (2011) 1.90
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs (2010) 1.62
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer (2006) 1.56
Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. Int J Colorectal Dis (2009) 1.50
Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol (2014) 1.26
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer (2003) 1.25
A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer (2006) 1.21
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer (2006) 1.21
A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer (2004) 1.17
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol (2010) 1.16
Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) (2013) 1.15
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer (2005) 1.15
A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer (2008) 1.13
Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer (2006) 1.11
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer (2005) 1.11
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer (2003) 1.10
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer (2007) 1.08
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer (2010) 1.05
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist (2011) 1.05
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol (2003) 1.04
Capecitabine: have we got the dose right? Nat Clin Pract Oncol (2008) 1.02
Personalized colon cancer care in 2010. Semin Oncol (2011) 1.01
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs (2010) 0.99
Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials. Oncol Lett (2012) 0.98
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemother Pharmacol (2007) 0.96
Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol (2006) 0.96
Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer (2005) 0.96
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer (2010) 0.96
Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis (2014) 0.95
A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study. J Gastrointest Oncol (2012) 0.95
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer (2009) 0.94
Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. Int J Colorectal Dis (2013) 0.94
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. Br J Cancer (2009) 0.94
Chemoradiotherapy for colorectal cancer. Gut (2005) 0.93
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer (2004) 0.93
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer (2006) 0.93
Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol (2011) 0.92
Capecitabine-based chemotherapy for metastatic colorectal cancer. J Cancer Res Clin Oncol (2010) 0.91
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br J Cancer (2009) 0.91
Advanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics. J Control Release (2011) 0.91
Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. Br J Cancer (2007) 0.91
Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. Korean J Intern Med (2007) 0.90
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer (2011) 0.90
First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol (2015) 0.90
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst (2015) 0.90
An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer (2007) 0.89
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin Cancer Res (2008) 0.89
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol (2009) 0.89
Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study. Int J Clin Oncol (2011) 0.89
The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials. Cancer Biother Radiopharm (2013) 0.88
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. Br J Cancer (2010) 0.88
Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol (2015) 0.88
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer (2012) 0.88
Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly. Best Pract Res Clin Gastroenterol (2009) 0.87
Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. Br J Clin Pharmacol (2006) 0.87
Trends in treatment and survival in older patients presenting with stage IV colorectal cancer. J Gastrointest Surg (2014) 0.87
Irinotecan-induced dysarthria. Case Rep Oncol (2012) 0.87
Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol (2006) 0.86
A phase I study of an oral simulated FOLFOX with high dose capecitabine. Invest New Drugs (2009) 0.86
A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer. Int J Colorectal Dis (2012) 0.86
Long noncoding RNA GAPLINC promotes invasion in colorectal cancer by targeting SNAI2 through binding with PSF and NONO. Oncotarget (2016) 0.86
Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointest Cancer Res (2007) 0.85
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer (2005) 0.85
Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer. J Korean Med Sci (2006) 0.85
Preoperative chemoradiotherapy in the management of localized rectal cancer: the new standard. Gastrointest Cancer Res (2007) 0.84
Advances in the treatment of metastatic colorectal cancer. Am J Ther (2009) 0.84
Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol (2009) 0.84
Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. Invest New Drugs (2003) 0.84
Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancer. Cancer Res Treat (2004) 0.83
Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study. BMC Cancer (2016) 0.83
Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol (2016) 0.83
Retrospective Analysis of Capecitabine and Radiation Therapy in the Treatment of Pancreatic Cancer. J Appl Res (2004) 0.82
Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) (2013) 0.81
Capecitabine in the management of colorectal cancer. Cancer Manag Res (2011) 0.81
Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer. J Gastrointest Cancer (2013) 0.81
A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer (2008) 0.81
Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. Onco Targets Ther (2014) 0.81
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study. J Korean Med Sci (2009) 0.81
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol (2014) 0.80
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. Anticancer Res (2010) 0.80
Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapy. Patient Prefer Adherence (2014) 0.79
Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis. World J Gastroenterol (2015) 0.79
Optimal use of adjuvant chemotherapy in stage II colorectal cancer. Int J Colorectal Dis (2011) 0.79
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. BMC Cancer (2006) 0.79
Capecitabine for locally advanced and metastatic colorectal cancer: A review. World J Gastrointest Oncol (2010) 0.79
Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. Br J Cancer (2006) 0.79
Management of locally advanced and metastatic colon cancer in elderly patients. World J Gastroenterol (2014) 0.79
Current directions in chemotherapy for colorectal cancer. J Gastroenterol (2006) 0.79
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients. Int J Clin Oncol (2012) 0.79
Management of colorectal cancer. Postgrad Med J (2002) 0.78
Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. World J Gastroenterol (2016) 0.78
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. J Cancer Res Clin Oncol (2009) 0.78
Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am (2010) 0.78
A review of the role of capecitabine in the treatment of colorectal cancer. Ther Clin Risk Manag (2007) 0.78
Role of oxaliplatin in the treatment of colorectal cancer. Ther Clin Risk Manag (2009) 0.78
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med (1998) 7.60
Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U S A (2005) 6.39
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures. Cell (1992) 5.24
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med (1996) 3.63
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol (1999) 3.62
Peak bone mass. Osteoporos Int (2000) 3.49
Predicting high-risk years for malaria in Colombia using parameters of El Niño Southern Oscillation. Trop Med Int Health (1997) 3.39
Changes in conserved region 2 of Escherichia coli sigma 70 affecting promoter recognition. J Mol Biol (1990) 3.04
Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A (2001) 3.04
Crystal structure of a beta-catenin/Tcf complex. Cell (2000) 2.93
Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem (1986) 2.88
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol (2002) 2.87
Three new members of the serine-aspartate repeat protein multigene family of Staphylococcus aureus. Microbiology (1998) 2.82
Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci U S A (1993) 2.79
Mitochondrial DNA molecules and virtual number of mitochondria per cell in mammalian cells. J Cell Physiol (1988) 2.59
Fatal infection with a novel, unidentified mycobacterium in a man with the acquired immunodeficiency syndrome. N Engl J Med (1990) 2.54
Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol (1998) 2.36
Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest (1998) 2.35
Safety and activity of saquinavir in HIV infection. Lancet (1995) 2.32
The General Medical Council's Performance Procedures: peer review of performance in the workplace. Med Educ (2001) 2.27
The assessment of poorly performing doctors: the development of the assessment programmes for the General Medical Council's Performance Procedures. Med Educ (2001) 2.26
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer (2006) 2.23
Nonspecific bronchial reactivity in occupational asthma. J Allergy Clin Immunol (1979) 2.22
Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet (2007) 2.15
Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg (2003) 2.13
Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol (1994) 2.11
Overbrushing. Br Dent J (2003) 2.04
The Lidcombe Programme of early stuttering intervention: methods and issues. Eur J Disord Commun (1997) 2.03
Accrediting research practices. Br J Gen Pract (1998) 1.97
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer (2001) 1.96
Research in the training of general surgeons: results of a survey. Ann R Coll Surg Engl (1996) 1.93
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer (2011) 1.90
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol (2005) 1.86
Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol (1985) 1.86
Evaluation of the delivery fee exemption policy in ghana: population estimates of changes in delivery service utilization in two regions. Ghana Med J (2007) 1.85
Mutations in WNT7A cause a range of limb malformations, including Fuhrmann syndrome and Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome. Am J Hum Genet (2006) 1.85
An immunodeficiency characterized by defective signal transduction in T lymphocytes. N Engl J Med (1989) 1.79
Cancer-related patient education: an overview of the last decade of evaluation and research. Oncol Nurs Forum (2001) 1.79
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline. Clin Oncol (R Coll Radiol) (2011) 1.73
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol (1998) 1.72
Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J (2007) 1.72
Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol (2009) 1.71
Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci U S A (1986) 1.71
A family kindred with ill-used children: the burden on the community. Br J Psychiatry (1973) 1.70
Poverty in rural areas. BMJ (1998) 1.66
Twenty-four-hour ambulatory blood pressure in men and women aged 17 to 80 years: the Allied Irish Bank Study. J Hypertens (1991) 1.66
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol (2012) 1.65
cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J Neurosci (1999) 1.63
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
Interaction among GSK-3, GBP, axin, and APC in Xenopus axis specification. J Cell Biol (2000) 1.63
Methods for the quantification of DNA double-strand breaks determined from the distribution of DNA fragment sizes measured by pulsed-field gel electrophoresis. Radiat Res (1995) 1.61
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol (1998) 1.61
Household income and health care expenditures in Mexico. Health Policy (1997) 1.58
Reaction of systemic lupus erythematosus antinative DNA antibodies with native DNA fragments from 20 to 1,200 base pairs. J Clin Invest (1980) 1.57
Forecasting disease risk for increased epidemic preparedness in public health. Adv Parasitol (2000) 1.54
Patients with advanced cancer: a survey of the understanding of their illness and expectations from palliative radiotherapy for symptomatic metastases. Clin Oncol (R Coll Radiol) (2001) 1.53
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer (2001) 1.52
Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene (2000) 1.50
Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol (1995) 1.50
Current indications and results of VATS in the evaluation and management of hemodynamically stable thoracic injuries. Eur J Cardiothorac Surg (2004) 1.48
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol (2003) 1.48
Data mining nursing care plans of end-of-life patients: a study to improve healthcare decision making. Int J Nurs Knowl (2012) 1.48
Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys (2000) 1.47
Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Eur J Cancer (2011) 1.46
Comparison of murine sarcoma viruses in nonproducer and S + L - -transformed cells. J Virol (1972) 1.44
A trial of blood pressure reduction in acute stroke. Age Ageing (2000) 1.44
Do radiologists still need to report chest x rays? Postgrad Med J (2009) 1.43
Simian virus 40 t antigen affects the sensitivity of cellular DNA synthesis to theophylline. J Virol (1979) 1.43
Conjugated estrogen reduces transfusion and coagulation factor requirements in orthotopic liver transplantation. Anesth Analg (1998) 1.43
Death from metastatic donor-derived ovarian cancer in a male kidney transplant recipient. Am J Transplant (2009) 1.41
Infective crystalline keratopathy secondary to non-tuberculous mycobacterium (Mycobacterium abscessus) in a non-traumatized eye. Eye (Lond) (2007) 1.40
Gastric intramural pH as indicator of early allograft viability in orthotopic liver transplantation. Transplantation (1994) 1.39
Use of the Hickman-Crawford critical care catheter in marrow transplant recipients: a pulmonary artery catheter-adaptable central venous access. Crit Care Med (1994) 1.39
Improvement in transfusion safety using a specially designed transfusion wristband. Transfus Med (2000) 1.38
Radiation therapy treatment verification imaging in Australia and New Zealand. J Med Imaging Radiat Oncol (2008) 1.38
Automated HPLC screening of newborns for sickle cell anemia and other hemoglobinopathies. Clin Chem (1996) 1.37
Spill-over of European bat lyssavirus type 1 into a stone marten (Martes foina) in Germany. J Vet Med B Infect Dis Vet Public Health (2004) 1.37
Accurate characterization of image intensifier distortion. Med Phys (1992) 1.35
Appointed czars, elected presidents and windows of opportunity. Br J Psychiatry (2001) 1.32
Non-valvular atrial fibrillation (NVAF) Br J Gen Pract (1997) 1.31
Presumed idiopathic outer lamellar defects of the fovea and chronic solar retinopathy: an OCT and fundus autofluorescence study. Br J Ophthalmol (2009) 1.31
Mitral valve aneurysm: clinical features, echocardiographic-pathologic correlations. J Am Coll Cardiol (1983) 1.31
Rural general practice. Br J Gen Pract (1994) 1.30
Deficiency of connexin43 gap junctions is an independent marker for breast tumors. Cancer Res (1999) 1.30
Cloning and characterization of the human and rat islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) genes. J Biol Chem (2001) 1.28
Cardiovascular effects of ozone exposure in human volunteers. Am J Respir Crit Care Med (1998) 1.28
Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med (1989) 1.28
Does prolonged breastfeeding adversely affect a child's nutritional status? Lancet (1988) 1.27
Bathtub drownings: report of seven cases. Pediatrics (1979) 1.25
The General Medical Council's Performance Procedures: the development and implementation of tests of competence with examples from general practice. Med Educ (2001) 1.25